| Leistung |
Fallzahl |
OPS-Schlüssel |
Info |
|
985
|
9-696.40 |
|
|
637
|
9-696.31 |
|
|
628
|
9-696.52 |
|
| Regelbehandlung bei psychischen und psychosomatischen Störungen und Verhaltensstörungen bei Kindern und Jugendlichen |
485
|
9-656 |
|
|
455
|
9-696.55 |
|
|
396
|
9-696.20 |
|
| Psychiatrisch-psychosomatische Intensivbehandlung bei psychischen und psychosomatischen Störungen und Verhaltensstörungen bei Kindern und Jugendlichen |
340
|
9-672 |
|
|
333
|
9-696.32 |
|
|
328
|
9-696.33 |
|
|
273
|
9-696.11 |
|
|
233
|
9-696.53 |
|
|
225
|
9-696.34 |
|
| Elektroenzephalographie [EEG]: Routine-EEG (10/20 Elektroden) |
214
|
1-207.0 |
|
|
210
|
9-696.35 |
|
|
186
|
9-696.56 |
|
|
147
|
9-696.10 |
|
|
141
|
9-696.58 |
|
|
135
|
9-696.36 |
|
|
134
|
9-696.0 |
|
|
128
|
9-696.30 |
|
|
118
|
9-696.54 |
|
|
111
|
9-696.51 |
|
|
111
|
9-696.57 |
|
|
106
|
9-696.12 |
|
|
93
|
9-696.37 |
|
|
88
|
9-696.59 |
|
|
86
|
9-696.50 |
|
|
84
|
9-696.13 |
|
|
80
|
9-696.38 |
|
|
77
|
9-696.5a |
|
|
62
|
9-696.5b |
|
|
49
|
9-696.39 |
|
|
43
|
9-696.5c |
|
|
39
|
9-696.15 |
|
|
33
|
9-696.41 |
|
|
30
|
9-696.3b |
|
|
26
|
9-696.17 |
|
|
25
|
9-696.14 |
|
|
24
|
9-696.5d |
|
|
23
|
9-696.3a |
|
|
23
|
9-696.5e |
|
|
23
|
9-696.5g |
|
|
22
|
9-696.5f |
|
|
19
|
9-984.8 |
|
|
17
|
9-984.7 |
|
|
14
|
9-696.16 |
|
|
12
|
9-696.19 |
|
|
12
|
9-696.3c |
|
|
11
|
9-696.5h |
|
|
8
|
9-696.18 |
|
|
8
|
9-696.3d |
|
|
6
|
9-696.3f |
|
|
6
|
9-696.3g |
|
|
5
|
9-696.21 |
|
|
5
|
9-696.3e |
|
|
5
|
9-696.5j |
|
|
5
|
9-696.5k |
|
|
5
|
9-696.5m |
|
|
4
|
9-696.1a |
|
| Native Magnetresonanztomographie des Schädels |
k.A.
|
3-800 |
|
| Applikation von Medikamenten, Liste 1: Adalimumab, parenteral: 440 mg oder mehr 440 mg oder mehr |
k.A.
|
6-001.dc |
|
|
k.A.
|
9-693.12 |
|
|
k.A.
|
9-696.1b |
|
|
k.A.
|
9-696.1d |
|
|
k.A.
|
9-696.1e |
|
|
k.A.
|
9-696.42 |
|
|
k.A.
|
9-696.5n |
|
|
k.A.
|
9-696.5p |
|
|
k.A.
|
9-696.5r |
|
|
k.A.
|
9-696.5s |
|
|
k.A.
|
9-696.5w |
|
|
k.A.
|
9-984.6 |
|
|
k.A.
|
9-984.9 |
|
|
k.A.
|
9-984.b |
|
